An interventional study of Ultrasound Scan in Type 1 Diabetes (T1D) and Type 2 Diabetes, Insulin Requiring, sponsored by Imperial College London. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-13.
Sponsored by Imperial College London · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Diabetes Mellitus, Type 1 by Imperial College London — 2 open to participants now, 2 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Imperial College London.
Among the 22 studies in Diabetes Mellitus, Type 1 by Imperial College London, this one has the largest planned enrollment of the 17 interventional ones that give a count, is the only one that started in 2026, is one of 16 with no phase, and was the 22nd registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →2 of the 22 studies in Diabetes Mellitus, Type 1 by Imperial College London are open now, in 1 country. Recruiting first, the newest first:
Imperial College London · Sites in United Kingdom
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is above the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 23 across the 17 interventional studies, 96 across the 5 observational. Of the 15 that completed or were terminated, 11 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
Imperial College London is the lead sponsor of 844 studies on the registry; 181 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
1 of the studies in Diabetes Mellitus, Type 1 by Imperial College London that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06782568Imperial College LondonAvoidance of Insulin-induced Lipohypertophy in People With Diabetes Using Ultrasound Scanning Within Diabetes Clinics | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies in Diabetes Mellitus, Type 1 by Imperial College London, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Diabetes is a common long-term health condition globally. Type 1 diabetes requires insulin treatment right from diagnosis. Similarly, many living with type 2 diabetes eventually require insulin injections as the condition progresses. A common but often underappreciated complication associated with insulin use is the formation of fatty tissue at injection sites, known as "Lipos," a shorthand for "Lipohypertrophy." These Lipos can interfere with insulin absorption, leading to an altered insulin action profile. This results in glucose fluctuations increasing the risk of both high and low glucose levels.
In current medical practice, Lipos are assessed through clinical examination, specifically by physically palpating the injection sites. Research indicates that approximately 40% of insulin-treated individuals may have Lipos. However, manual palpation can often overlook these fatty deposits. Ultrasound scanning (USS) presents a more effective method for detecting Lipos. Studies that have employed ultrasound scanning have reported a much higher prevalence, reaching up to 86%.
The primary goal of this study is to ascertain whether the avoidance of ultrasound-identified Lipos can improve glucose regulation. The focus will be on individuals using continuous glucose monitoring who exhibit high glucose fluctuations and less time within their target range. By focusing on this population, the chances of identifying those with Lipos will increase.
Participants will undergo a clinical examination followed by an ultrasound scan. Those found to have Lipos will receive guidance on avoiding those sites and education on insulin injection techniques. Glucose data will be collected periodically over the next 24 weeks. After this period, participants will return for a follow-up ultrasound scan. Additionally, members of the diabetes care team will be trained to conduct the ultrasound scans. Data from this study may also be utilized to develop artificial intelligence algorithms aimed at identifying Lipos in future ultrasound scans.
This will be a single-centre, prospective, open-label, non-randomized feasibility study. Participants will be recruited through diabetes clinics at Imperial College Healthcare NHS Trust, London, UK. Written informed consent will be obtained.
Key Inclusion criteria:
Exclusion criteria:
The study will be conducted at Imperial College Healthcare NHS Trust. All consented participants will enter a 2-week run-in period where baseline demographic data will be collected and baseline clinical examination and USS will be performed. Continuous glucose monitoring (CGM) data from patients own CGM device will be collected and HbA1c test performed if not done within last 2 weeks. A map of Lipo site will be created and participant advised to avoid these sites for next 24 weeks. CGM data at 4 weeks and 12 weeks post-baseline USS scan will be collected either remotely or in-person. End of study USS, CGM data collection and HbA1c will be conducted at 24 weeks after the baseline USS.
Details of study visits:
Visit 1: Screening \& Enrolment
Potentially eligible participants will attend the diabetes clinic or clinical research facility or will be seen during their scheduled clinic appointments as preferred by participants and availability of clinical space. Following written informed consent, baseline clinical data will be collected from all participants. Information sheets will be provided in advance to potential participants. Following informed consent, those interested in participating will be assessed to determine if they meet the inclusion criteria listed above. A blood sample will be taken for HbA1c \& kidney function if no result is available within the last two weeks. Women of childbearing potential will have a βHCG test to exclude pregnancy.
The following data will be recorded in the CRF:
General Clinical
Diabetes clinical
CGM data Glucose data from the CGM device will be downloaded and stored in an approved computer. Summary CGM statistics using usual clinical software (Carelink, Libreview, Dexcom Clarity) will also be recorded for last 4 weeks.
Visit 2: Baseline Ultrasound Scan (USS)
Participants will have a clinical examination of the insulin injection sites followed by USS of the injection sites. Findings will be documented in the case report forms, and individual maps of injection sites with Lipos created, and participants will be advised to avoid Lipo sites for the next 24 weeks. Insulin needle lengths (4 mm needles advised if on longer needles) and injection techniques will also be paid attention to.
If no significant lipohypertophy (LH) is detected by USS, participants will take no further part in the study
Visit 3: Four-week follow visit
This visit could be done as a remote visit. Glucose data from the CGM device will be downloaded and stored. Summary CGM statistics using usual clinical software (Carelink, Libreview, Dexcom Clarity) will also be recorded for last 4 weeks.
Visit 4: 12-week follow visit
This visit could be done as a remote visit. Glucose data from the CGM device will be downloaded and stored. Summary CGM statistics using usual clinical software (Carelink, Libreview, Dexcom Clarity) will also be recorded for last 4 weeks.
Visit 5: End of Study Visit (24-weeks)
All participants will have blood sample taken for HbA1c. Glucose data from the CGM device will be downloaded and stored. Summary CGM statistics using usual clinical software (Carelink, Libreview, Dexcom Clarity) will also be recorded for last 4 weeks. Participants will have a clinical examination of the insulin injection sites followed by USS of the injection sites. Information about current insulin doses will also be collected. This will be the end of study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will undergo clinical examination followed by ultrasound scanning (USS) of the injection sites at baseline. If there is no significant lipohypertophy (LH) detected by USS, participants will take no further part in the study. If there is LH detected on USS, an individualised map of LH sites and clear sites will be drawn, and the participant will be asked to avoid LH sites for the next 6 months. Follow up remote/virtual/F2F visits will be conducted at 1 and 3 months. The final visit at 6 months will consist of a repeat clinical examination followed by a repeat USS.
Diagnostic Test: Ultrasound Scan
Participants will undergo an ultrasound scan of insulin injection sites at baseline and after 6 months.
Time in Range (3.9 to 10.0 mmol/l)
Time spent in the target glucose range between 3.9 to 10.0 mmol/l (70 to 180 mg/dl) based on sensor glucose levels for the last 4 weeks of the 24 week study period
Time frame: From enrollment to the end of treatment at 24 weeks
HbA1c
Change in HbA1c from baseline
Time frame: From enrollment to the end of treatment at 24 weeks
Mean glucose
Mean glucose levels at 24 weeks
Time frame: From enrollment to the end of treatment at 24 weeks
Time above range (Level 1)
Time spent above target glucose (10.0 mmol/l) (180 mg/dl) (Level 1 hyperglycaemia)
Time frame: From enrollment to the end of treatment at 24 weeks
Time above range (Level 2)
Time spent above target glucose (13.9 mmol/l) (250 mg/dl) (Level 2 hyperglycaemia)
Time frame: From enrollment to the end of treatment at 24 weeks
Time below range (Level 1)
Time spent below target glucose (\<3.9mmol/l) (\<70mg/dl) (Level 1 hypoglycaemia)
Time frame: From enrollment to the end of treatment at 24 weeks
Time below range (Level 2)
Time spent below target glucose (\<3.0mmol/l) (\<54mg/dl) (Level 2 hypoglycaemia)
Time frame: From enrollment to the end of treatment at 24 weeks
Insulin doses
Average total daily insulin dose, basal and bolus dose
Time frame: From enrollment to the end of treatment at 24 weeks
Severe Hypoglycaemia
Frequency of severe hypoglycaemic episodes as defined by the American Diabetes Association
Time frame: From enrollment to the end of treatment at 24 weeks
Resolution of Lipohypertrophy (LH)
Resolution rate of Lipohypertrophy (% of participants affected and number of distinct LH sites per participant)
Time frame: From enrollment to the end of treatment at 24 weeks
Time in Range (3.9 to 10.0 mmol/l)
Time spent in the target glucose range between 3.9 to 10.0 mmol/l (70 to 180 mg/dl) based on sensor glucose levels
Time frame: From enrollment to the end of treatment at 12 weeks
Time in Range (3.9 to 10.0 mmol/l)
Time spent in the target glucose range between 3.9 to 10.0 mmol/l (70 to 180 mg/dl) based on sensor glucose levels
Time frame: From enrollment to the end of treatment at 4 weeks
Glucose variability
Coefficient of Variation of glucose levels at 24 weeks
Time frame: From enrollment to the end of treatment at 24 weeks
Adverse Events
Adverse events will be tabulated and reported
Time frame: From enrollment to the end of treatment at 24 weeks
Plan to share: No — This is a single-arm feasibility study.
Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.
Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 11 months is below that.
Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.